SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, +14

Clinical Cancer Research

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4

Francesca Zanconato, Giusy Battilana, Mattia Forcato, +14

Nature Medicine

Tumor BiologyTranscriptional RegulationSignal TransductionCell RegulationTranscriptional Addiction +11

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies

Sven Christian, Claudia Merz, Laura Evans, +17

Leukemia

Mixed-phenotype Acute LeukemiaGeneticsPathologyAll-trans Retinoic AcidTumor Biology +15

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

Patricia Vrignaud, Dorothée Sémiond, Pascale Lejeune, +7

Clinical Cancer Research

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking, +17

Molecular Cancer Therapeutics

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, +15

Clinical Cancer Research

Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors.

Sylvie Reveneau, Laurent Arnould, G Jolimoy, +5

PubMed

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

Hendrik Borgmann, Nada Lallous, Deniz Özistanbullu, +8

European Urology

Androgen ReceptorNovel Inhibitor DarolutamideUrologyGenitourinary CancerMedicine +7

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Tatsuo Sugawara, Simon J. Baumgart, Ekaterina Nevedomskaya, +5

International Journal of Cancer

Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography

S. Lavisse, Pascale Lejeune, Valérie Rouffiac, +9

Investigative Radiology